Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo

  • Authors:
    • Kun‑Huang Yan
    • Yung‑Wei Lin
    • Chi‑Hao Hsiao
    • Yu‑Ching Wen
    • Ke‑Hsun Lin
    • Chung‑Chi Liu
    • Mao‑Chih Hsieh
    • Chih‑Jung Yao
    • Ming‑De Yan
    • Gi‑Ming Lai
    • Shuang‑En Chuang
    • Liang‑Ming Lee
  • View Affiliations

  • Published online on: March 15, 2013     https://doi.org/10.3892/ol.2013.1259
  • Pages: 1567-1571
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'‑dichlorofluorescein‑diacetate (DCFH‑DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through non‑apoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.
View Figures
View References

Related Articles

Journal Cover

May 2013
Volume 5 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yan KH, Lin YW, Hsiao CH, Wen YC, Lin KH, Liu CC, Hsieh MC, Yao CJ, Yan MD, Lai GM, Lai GM, et al: Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo. Oncol Lett 5: 1567-1571, 2013
APA
Yan, K., Lin, Y., Hsiao, C., Wen, Y., Lin, K., Liu, C. ... Lee, L. (2013). Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo. Oncology Letters, 5, 1567-1571. https://doi.org/10.3892/ol.2013.1259
MLA
Yan, K., Lin, Y., Hsiao, C., Wen, Y., Lin, K., Liu, C., Hsieh, M., Yao, C., Yan, M., Lai, G., Chuang, S., Lee, L."Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo". Oncology Letters 5.5 (2013): 1567-1571.
Chicago
Yan, K., Lin, Y., Hsiao, C., Wen, Y., Lin, K., Liu, C., Hsieh, M., Yao, C., Yan, M., Lai, G., Chuang, S., Lee, L."Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo". Oncology Letters 5, no. 5 (2013): 1567-1571. https://doi.org/10.3892/ol.2013.1259